Will you give a trial of tirzepatide in patients with PsA and obesity who have a partial response to bDMARD rather than switching their immunosuppressive regimen?

I don't believe the data on the magnitude of the benefit of GLP-1 agonists in arthritis symptoms is sufficient to suggest that adding one of these agents would be preferable to changing DMARDs in a patient with inadequate response.

Yes, we will give a GLP-1RA in selected patients who have an inadequate response to initial bDMARD or tsDMARD therapy. The major barrier is insurance approval.

Weight management is an essential treatment modality for psoriatic disease and patients who suffer from obesity. It is a call to action by all specialists and remains a primary recommendation in all of our guidelines. As long as the BMI remains high, it can worsen disease activity and lead to treatm...